Gariot P, Pointel J P, Barrat E, Drouin P, Debry G
Biomed Pharmacother. 1984;38(2):101-6.
In rodents fenofibrate shares with other triglyceride-lowering agents the potential to increase the liver peroxisome population. It was therefore of interest to look for this effect in hyperlipoproteinemic patients receiving this drug. Light and electron microscopy of liver biopsies from a group of 10 patients treated with fenofibrate and from another group of 13 receiving diet only, show no morphological difference between both groups. In contrast with the rodent data the morphometric study reveals no significant changes in the number (fenofibrate group: 7.96 10(10) cm-3; group receiving diet alone: 8.41 10(10) peroxisomes per cm3 of liver tissue) or in the size (fenofibrate group: diameter = 0.53 +/- 0.07 micron; group receiving diet alone: 0.50 +/- 0.06) of peroxisomes. The difference between our results and those obtained consistently in rodents may be due to the relatively low dose in man and/or a species-dependant difference in enzyme content of liver peroxisomes, itself related to an apparent difference in the way in which lipids are handled.
在啮齿动物中，非诺贝特与其他降甘油三酯药物一样，具有增加肝脏过氧化物酶体数量的潜力。因此，在接受该药物治疗的高脂血症患者中寻找这种效应很有意义。对一组10名接受非诺贝特治疗的患者和另一组仅接受饮食治疗的13名患者的肝脏活检标本进行光镜和电镜检查，结果显示两组之间没有形态学差异。与啮齿动物的数据相反，形态计量学研究表明，过氧化物酶体的数量（非诺贝特组：7.96×10¹⁰个/cm³；仅接受饮食治疗组：8.41×10¹⁰个/cm³肝组织）或大小（非诺贝特组：直径 = 0.53±0.07微米；仅接受饮食治疗组：0.50±0.06微米）均无显著变化。我们的结果与在啮齿动物中一致获得的结果之间的差异，可能是由于人类使用的剂量相对较低和/或肝脏过氧化物酶体酶含量存在物种依赖性差异，这本身与脂质处理方式的明显差异有关。
